OPKO Health Q2 revenue $156.8M down 14% YoY; net loss includes $91.7M convertible note charge

OPKO HEALTH, INC.

2025-Q2 EPS reported -$0.31 revenue$306,759,000

Consolidated revenue $156.8M vs $182.2M in Q2 2024; net loss $148.4M ($0.19/share) vs $10.3M loss ($0.01) prior year, including $91.7M non-recurring convertible note expense.
Diagnostics revenue $101.1M (-22% YoY) on lower clinical test volume from BioReference asset sale; operating loss improved to $18.2M from $26.6M.
Pharmaceuticals revenue $40.7M (flat); operating loss $28.7M vs $24.8M, driven by higher R&D for pipeline programs.
Board authorized additional $100M share repurchase, total capacity $200M; $58.5M repurchased through June 30.
FDA approved 4Kscore Test without DRE; Merck Phase 1 EBV vaccine and multiple pipeline programs advancing.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.